Business, energy, technology, markets and global industry news from Business News Today

acute liver failure

PharmaDeviceNews acute liver failure
Sarepta enrolls non-ambulatory Duchenne patients in ELEVIDYS sirolimus safety study
Pharma & Biotech

Sarepta’s sirolimus gambit: Can enhanced immunosuppression rescue ELEVIDYS for non-ambulatory Duchenne patients?

Sarepta's ELEVIDYS Cohort 8 targets non-ambulatory Duchenne patients with a sirolimus regimen. What the trial design reveals about the path to label restoration.

Read More
Pharma & Biotech

How United Therapeutics is betting on scaffold-based liver support in high-mortality ALF

United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.

Read More